Organogenesis (ORGO)
(Delayed Data from NSDQ)
$2.91 USD
-0.04 (-1.36%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $2.90 -0.01 (-0.34%) 7:58 PM ET
4-Sell of 5 4
B Value F Growth B Momentum C VGM
Price, Consensus and EPS Surprise
ORGO 2.91 -0.04(-1.36%)
Will ORGO be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ORGO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ORGO
Organogenesis (ORGO) Reports Break-Even Earnings for Q4
Foghorn Therapeutics Inc. (FHTX) Moves 22.7% Higher: Will This Strength Last?
ORGO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are You Looking for a Top Momentum Pick? Why Organogenesis (ORGO) is a Great Choice
Best Momentum Stocks to Buy for January 5th
New Strong Buy Stocks for January 5th
Other News for ORGO
Lake Street starts Organogenesis with Buy on competitive advantages
Organogenesis initiated with bullish view at Lake Street
Organogenesis Shareholders Affirm Governance and Strategy
Organogenesis Holdings: Small-Cap Biotech With Inconsistent Earnings And A Powerful Catalyst
Organogenesis Holdings Inc. to Participate in the Truist Securities MedTech Conference